Cogent Biosciences
COGT
146 hedge funds and large institutions have $734M invested in Cogent Biosciences in 2024 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 63 increasing their positions, 37 reducing their positions, and 30 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
70% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 37
56% more call options, than puts
Call options by funds: $1.76M | Put options by funds: $1.13M
34% more capital invested
Capital invested by funds: $547M → $734M (+$187M)
10% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 30
1% more funds holding
Funds holding: 144 → 146 (+2)
2.93% less ownership
Funds ownership: 108.08% → 105.14% (-2.9%)
Top Buyers
Top Sellers
| 1 |
SCM
Suvretta Capital Management
New York
|
-$21M |
| 2 |
Morgan Stanley
New York
|
-$16.5M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$13.1M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$6.54M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$3.15M |
COGT Hedge Fund Activity: Q1 2024 in Review
146 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q1 2024, worth a combined $734M — up 34% from $547M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new COGT positions and 30 closed out — a net gain of 3 holders — while 63 added to existing stakes and 37 trimmed.
The largest buyer was State Street, adding an estimated $21.5M. The largest seller was Suvretta Capital Management, cutting an estimated $21M.
- 146 institutional investors held Cogent Biosciences (COGT) as of Q1 2024, up from 144 in Q4 2023.
- Funds reported $734M of Cogent Biosciences stock for Q1 2024, up 34% quarter-over-quarter.
- 33 funds opened new Cogent Biosciences positions in Q1 2024 and 30 closed out, a net change of +3 holders.
- The largest Cogent Biosciences buyer in Q1 2024 was State Street, an estimated $21.5M added.
- The largest Cogent Biosciences seller in Q1 2024 was Suvretta Capital Management, an estimated $21M sold.
Based on aggregated 13F filings for Q1 2024.